Author/Authors :
Park، نويسنده , , Sae-Gwang and Jung، نويسنده , , Jeong-Joo and Won، نويسنده , , Hae Jeong and Kang، نويسنده , , Mi Seon and Seo، نويسنده , , Su-Kil and Choi، نويسنده , , Il-Whan and Eun، نويسنده , , Choong Ki and Ahn، نويسنده , , Ki Jung and Park، نويسنده , , Cheol-Woo and Lee، نويسنده , , Soo-Woong and Lew، نويسنده , , Young S. and Bae، نويسنده , , Ill-Ju and Choi، نويسنده , , In-Hak، نويسنده ,
Abstract :
Tetras (tetra-arsenic oxide, As4O6) is a derivative of arsenic used in Korean traditional medicine for the treatment of cancer, but its mechanism remains largely undefined. Recently, a similar arsenic derivative, diarsenic trioxide (As2O3, ATO), has been shown to mediate anti-tumor activity, therefore reigniting interest in the therapeutic effect of arsenic compounds. Here we report that Tetras can effectively mediate an anti-vascular effect on tumors, leading to delay in tumor growth and increased survival. Our study demonstrates for the first time the potential use of Tetras as a radiation therapy enhancement agent for solid tumors. These findings reveal an unappreciated role of Tetras in cancer therapy and its potential application to radiotherapy in achieving local tumor control.
